ANSWER: D

Rationale:

Imatinib (Gleevec) is the prototypical targeted tyrosine kinase inhibitor and one of the landmark achievements in cancer pharmacology. CML is driven by the BCR-ABL fusion kinase created by the Philadelphia chromosome -- a reciprocal translocation between chromosomes 9 and 22 that fuses the BCR gene to the ABL1 (Abelson murine leukemia viral oncogene homolog 1) tyrosine kinase gene. The resulting BCR-ABL protein has constitutively active tyrosine kinase activity -- it continuously phosphorylates downstream signaling proteins (RAS, MAPK, PI3K/AKT, STAT5 (signal transducer and activator of transcription 5)) that drive unchecked proliferation and apoptosis resistance. Imatinib was rationally designed to fit into the ATP-binding pocket of BCR-ABL and lock it in the inactive (DFG-out -- named for the Asp-Phe-Gly motif in the kinase activation loop) conformation, preventing ATP binding and substrate phosphorylation. This targeted mechanism produces remarkable clinical efficacy with much lower toxicity than conventional cytotoxic chemotherapy. Imatinib also inhibits KIT (stem cell factor receptor) and PDGFR (platelet-derived growth factor receptor) kinases, explaining its use in gastrointestinal stromal tumors (GIST). Options A, B, and E describe cytotoxic drugs with non-kinase mechanisms.

• Option C: Option C is incorrect -- rituximab is a monoclonal antibody targeting a cell surface antigen, not a kinase inhibitor; it works through different mechanisms (ADCC (antibody-dependent cellular cytotoxicity), complement activation, direct apoptosis induction) in B-cell malignancies.

ANSWER: A

Rationale:

Trastuzumab (Herceptin) is a humanized monoclonal antibody that binds specifically to the extracellular domain IV of the HER2 (human epidermal growth factor receptor 2) protein. HER2, also called ErbB2, is a receptor tyrosine kinase that is amplified in approximately 15-20% of breast cancers and 10-15% of gastric/gastroesophageal cancers. When amplified, HER2 drives constitutive receptor dimerization and activation of downstream proliferative signaling (PI3K/AKT/mTOR, RAS/MAPK). Trastuzumab binding to domain IV prevents HER2 dimerization and receptor activation, blocks downstream signaling, and recruits natural killer cells and macrophages through Fc receptor-mediated ADCC (antibody-dependent cellular cytotoxicity). Trastuzumab also promotes HER2 internalization and degradation. Importantly, trastuzumab only works in tumors with true HER2 protein overexpression or gene amplification -- accurate HER2 testing (IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization)) is required before treatment.

• Option B: Option B is incorrect -- trastuzumab is a monoclonal antibody that targets the extracellular domain, not the intracellular kinase domain; lapatinib and neratinib are examples of small-molecule TKIs that target the intracellular kinase domain.
• Option C: Option C is incorrect -- trastuzumab does not directly target RAS; it acts upstream at the receptor.
• Option D: Option D is incorrect -- trastuzumab has no activity at the estrogen receptor; it targets the HER2 extracellular domain regardless of hormone receptor status.
• Option E: Option E is incorrect -- trastuzumab does not directly inhibit PI3K; it acts at the receptor level upstream of PI3K.

ANSWER: E

Rationale:

Nuclear receptors are intracellular receptors that, upon ligand binding, translocate to the nucleus and directly regulate gene transcription. The glucocorticoid receptor (GR) is the prototype pharmacological nuclear receptor target. Prednisolone (and other glucocorticoids -- dexamethasone, hydrocortisone, methylprednisolone) binds the ligand-binding domain of the cytoplasmic GR. Ligand binding induces a conformational change, dissociation of heat shock proteins (HSP90 and HSP70 -- chaperone proteins that maintain the unliganded GR in the cytoplasm) that hold the receptor in the cytoplasm, and translocation of the drug-receptor complex to the nucleus. In the nucleus, GR homodimers bind palindromic GREs and activate transcription of anti-inflammatory genes. GR also interacts directly with transcription factors NF-kappaB and AP-1, tethering them and inhibiting their transcriptional activity (transrepression) -- the mechanism underlying most anti-inflammatory effects. This nuclear receptor mechanism explains the delayed onset of glucocorticoid effects (hours for gene transcription to produce protein changes) and their broad range of metabolic, immune, and endocrine effects. Other nuclear receptor drug targets include thyroid hormone receptors (levothyroxine), androgen receptors (testosterone, enzalutamide), estrogen receptors (tamoxifen), PPARgamma (pioglitazone), and vitamin D receptors (calcitriol). Options A, B, and C describe cell-surface receptor or transporter mechanisms with no nuclear receptor involvement.

• Option D: Option D is incorrect -- atorvastatin inhibits HMG-CoA reductase, a cytoplasmic/ER-membrane enzyme; while statins do produce some downstream nuclear effects via sterol regulatory element-binding proteins (SREBPs), the primary pharmacological target is an enzyme, not a nuclear receptor.

ANSWER: C

Rationale:

Tamoxifen is the prototypical selective estrogen receptor modulator (SERM). The SERM concept is fundamental to pharmacology: the same drug binding the same receptor (ER-alpha and ER-beta) can produce agonist effects in some tissues and antagonist effects in others. In breast tissue, tamoxifen acts as an ER antagonist -- it competitively blocks estradiol binding and recruits co-repressor proteins to ER-responsive gene promoters, inhibiting transcription of proliferative genes and reducing breast cancer cell growth. In bone, tamoxifen acts as an ER partial agonist -- it maintains bone mineral density by stimulating osteoblast activity and reducing osteoclast activity, reducing fracture risk in postmenopausal women. In the uterus, tamoxifen acts as an ER partial agonist -- it stimulates endometrial proliferation, increasing the risk of endometrial cancer with long-term use. In the liver, it acts as an ER agonist, reducing LDL cholesterol. This tissue-specific pharmacodynamic behavior reflects differences in the relative abundance of ER co-activator proteins (SRC-1 (steroid receptor coactivator-1), CBP (CREB-binding protein), p300) and co-repressor proteins (NCoR (nuclear receptor corepressor), SMRT (silencing mediator for retinoid and thyroid receptors)) in different cell types -- the balance of co-activator vs co-repressor recruitment by the tamoxifen-ER complex determines whether transcription is activated or repressed at any given promoter.

• Option A: Option A is incorrect -- tamoxifen is tissue-selective, not a uniform antagonist; its partial agonist activity in the uterus produces endometrial cancer risk.
• Option B: Option B is incorrect -- aromatase inhibitors (letrozole, anastrozole, exemestane) reduce estrogen synthesis; tamoxifen does not inhibit aromatase.
• Option D: Option D is incorrect -- fulvestrant (Faslodex) is the SERD that degrades ER; tamoxifen does not degrade the receptor.
• Option E: Option E is incorrect -- tamoxifen is a synthetic drug, not a phytoestrogen, and is a first-line prescription treatment.

ANSWER: B

Rationale:

Ruxolitinib is a JAK1/JAK2 inhibitor approved for myelofibrosis and polycythemia vera (PV). Unlike tofacitinib (which primarily targets JAK1/JAK3 for inflammatory conditions), ruxolitinib's JAK2 selectivity makes it particularly useful for myeloproliferative neoplasms driven by activating JAK2 mutations. The JAK2 V617F mutation -- a valine-to-phenylalanine substitution at position 617 -- is present in approximately 95% of PV cases and 50-60% of myelofibrosis cases. This point mutation renders JAK2 constitutively active, driving continuous STAT5, STAT3 (signal transducer and activator of transcription 3), and STAT1 (signal transducer and activator of transcription 1) signaling independent of normal erythropoietin, thrombopoietin, and other cytokine receptor engagement. The result is uncontrolled proliferation of myeloid progenitors, splenomegaly (from extramedullary hematopoiesis), and constitutional symptoms. Ruxolitinib competitively occupies the ATP-binding site of JAK1 and JAK2, reducing STAT phosphorylation and myeloproliferative signaling. It produces significant reductions in splenomegaly and improves constitutional symptoms (fatigue, night sweats, pruritus) in both conditions.

• Option A: Option A is incorrect -- tocilizumab (not ruxolitinib) is the anti-IL-6 receptor monoclonal antibody used in RA; sarilumab is another example.
• Option C: Option C is incorrect -- BCR-ABL inhibitors (imatinib, dasatinib, nilotinib, ponatinib) are used in CML; ruxolitinib does not inhibit BCR-ABL.
• Option D: Option D is incorrect -- BRAF V600E inhibitors (vemurafenib, dabrafenib) are used in melanoma; ruxolitinib does not inhibit BRAF.
• Option E: Option E is incorrect -- proteasome inhibitors (bortezomib, carfilzomib) are used in multiple myeloma; ruxolitinib does not inhibit the proteasome.

ANSWER: A

Rationale:

Thyroid hormone receptors (TRalpha1, TRalpha2, TRbeta1, TRbeta2) are members of the nuclear receptor superfamily. They are constitutively located in the nucleus and bind to thyroid hormone response elements (TREs) in DNA even in the absence of ligand -- in the unliganded state, TR-RXR (retinoid X receptor) heterodimers recruit co-repressors and suppress transcription of thyroid hormone-responsive genes. When T3 (or T4 converted to T3) binds the TR ligand-binding domain, co-repressors are released and co-activators are recruited, activating transcription. Levothyroxine (synthetic T4) is the standard replacement therapy for hypothyroidism. After absorption, T4 is peripherally converted to T3 (the biologically more active form with approximately 10-fold higher TR affinity) by tissue deiodinases (types I, II, and III). T3 then binds TR in target tissue nuclei, activating transcription of genes regulating basal metabolic rate (increasing oxygen consumption), cardiac chronotropy and inotropy (TRalpha-dependent), cholesterol metabolism (TRbeta-dependent), and brain development. The tissue distribution of TR subtypes explains the targeted approach of TRbeta-selective agonists (such as resmetirom) for metabolic liver disease -- TRbeta activation in liver reduces cholesterol and triglycerides without TRalpha-mediated cardiac effects. Options B, C, D, and E all describe drugs that act in or on the thyroid gland itself (on enzymes, iodide transport, or through radiation) rather than on thyroid hormone nuclear receptors in peripheral target tissues.

ANSWER: E

Rationale:

Bevacizumab (Avastin) is a humanized monoclonal antibody that targets VEGF-A (vascular endothelial growth factor-A) in the circulation, neutralizing free VEGF before it can bind and activate its endothelial cell receptors (VEGFR1/Flt-1 and VEGFR2/KDR). Tumor-induced angiogenesis is essential for tumor growth beyond 2-3 mm -- tumors secrete VEGF to recruit new blood vessels that deliver oxygen and nutrients and remove metabolic waste. By sequestering circulating VEGF, bevacizumab prevents the formation and maintenance of tumor vasculature, depriving tumors of blood supply. Bevacizumab is used in combination with cytotoxic chemotherapy in multiple tumor types: metastatic colorectal cancer (first approved indication), non-squamous non-small cell lung cancer, glioblastoma (recurrent), ovarian cancer, and cervical cancer. Its toxicities reflect on-target VEGF inhibition: hypertension (VEGF normally maintains endothelial nitric oxide), impaired wound healing, arterial thromboembolism, and proteinuria.

• Option A: Option A is incorrect -- cetuximab and panitumumab target EGFR, not bevacizumab.
• Option B: Option B is incorrect -- trastuzumab and pertuzumab target HER2, not bevacizumab.
• Option C: Option C is incorrect -- no approved monoclonal antibody targets BCR-ABL; BCR-ABL inhibitors are all small molecules.
• Option D: Option D is incorrect -- rituximab, obinutuzumab, and ofatumumab target CD20, not bevacizumab.

ANSWER: D

Rationale:

Pioglitazone is a thiazolidinedione (TZD, also called glitazone) and a full agonist at PPARgamma (peroxisome proliferator-activated receptor gamma) -- a nuclear receptor that is the master regulator of adipocyte differentiation and lipid storage. PPARgamma forms obligate heterodimers with RXR (retinoid X receptor) and binds PPRE (PPAR response elements) in target gene promoters. Pioglitazone binding to PPARgamma activates transcription of genes encoding adiponectin (an insulin-sensitizing adipokine), fatty acid transporters, and enzymes involved in triglyceride storage in adipocytes. By promoting appropriate fat storage in adipocytes rather than ectopic accumulation in liver and muscle, pioglitazone reduces the lipotoxicity that contributes to insulin resistance. The resulting improvement in insulin sensitivity reduces hepatic glucose output and enhances peripheral glucose uptake. Pioglitazone's additional PPARalpha activity (though weaker than its PPARgamma effect) contributes to improvements in triglycerides and HDL cholesterol. Pioglitazone is used in type 2 diabetes; its major adverse effects are fluid retention (edema, heart failure exacerbation), weight gain (through adipogenesis), and increased fracture risk in women.

• Option A: Option A describes metformin (biguanide/AMPK).
• Option B: Option B describes sulfonylureas (glipizide, glyburide).
• Option C: Option C describes GLP-1 receptor agonists (semaglutide, liraglutide).
• Option E: Option E describes DPP-4 inhibitors (sitagliptin, saxagliptin).

ANSWER: C

Rationale:

Sotorasib (Lumakras) represents a major pharmacological achievement: the first approved therapy specifically targeting KRAS, a protein considered undruggable for decades due to its smooth surface with no obvious drug-binding pockets and its picomolar GTP affinity making competitive inhibition impractical. KRAS G12C is a point mutation in which glycine at codon 12 is replaced by cysteine -- present in approximately 13% of NSCLC (non-small cell lung cancer), 3% of colorectal cancer, and 2% of pancreatic cancer. Sotorasib exploits the unique cysteine residue introduced by the G12C mutation -- it forms an irreversible covalent bond with this cysteine, locking mutant KRAS in the inactive GDP-bound state and preventing the GTP loading that activates downstream MAPK and PI3K signaling. Because wild-type KRAS (which has glycine at position 12) does not have the reactive cysteine, sotorasib selectively inhibits the mutant protein with minimal effect on normal KRAS signaling. This mutation-specific covalent targeting strategy is a template for future oncology drug development.

• Option A: Option A is incorrect -- imatinib does not inhibit BRAF; vemurafenib and dabrafenib are BRAF inhibitors; CML is driven by BCR-ABL, not BRAF.
• Option B: Option B is incorrect -- vemurafenib targets BRAF V600E in melanoma, not BCR-ABL; these are completely different kinases.
• Option D: Option D is incorrect -- EGFR exon 19 deletions occur primarily in NSCLC (not colorectal cancer) and are treated with EGFR TKIs (erlotinib, gefitinib, osimertinib); cetuximab targets EGFR in KRAS wild-type colorectal cancer (not EGFR-mutant NSCLC).
• Option E: Option E is incorrect -- trastuzumab's primary approved indications are HER2-positive breast cancer and HER2-positive gastric/gastroesophageal cancer; it is not the primary approved therapy for HER2-amplified pancreatic cancer.

ANSWER: B

Rationale:

HPA (hypothalamic-pituitary-adrenal) axis suppression and adrenal insufficiency is one of the most clinically important adverse effects of long-term glucocorticoid therapy and the pharmacodynamic basis for the cardinal rule of never abruptly stopping chronic steroid therapy. The mechanism involves negative feedback at multiple levels: exogenous glucocorticoids bind GRs in the hypothalamus and anterior pituitary, suppressing CRH and ACTH secretion. Without ACTH stimulation, the adrenal cortex atrophies -- the zona fasciculata (cortisol-producing zone) regresses, losing its capacity for cortisol synthesis. The degree and duration of HPA suppression depends on dose, duration, dosing schedule, and route of administration. With prolonged suppression, the adrenal glands may require months to recover full cortisol secretory capacity even after exogenous glucocorticoid is discontinued. During this recovery period, the patient is at risk for adrenal crisis -- particularly during physiological stress (surgery, infection, trauma) when cortisol requirements are greatly increased but the recovering adrenal cannot respond. Clinical features of adrenal crisis include hypotension (cortisol supports vascular tone and catecholamine response), hyponatremia, hyperkalemia (without cortisol's mineralocorticoid effect), and hypoglycemia. Management requires stress-dose glucocorticoid replacement (typically hydrocortisone 50-100 mg IV every 6-8 hours) and fluid resuscitation. The clinical protocol for preventing this is gradual glucocorticoid tapering over weeks to months, allowing the HPA axis to gradually recover.

• Option A: Option A is incorrect -- the atrophied adrenal glands cannot overproduce cortisol; the consequence is insufficient cortisol, not excess.
• Option C: Option C is incorrect -- GR upregulation after steroid withdrawal does not produce clinical glucocorticoid excess; the adrenal atrophy means insufficient endogenous cortisol to bind even upregulated receptors.
• Option D: Option D is incorrect -- glucocorticoids do suppress TSH but through a completely distinct mechanism (suppressing TRH (thyrotropin-releasing hormone) and TSH at the hypothalamus/pituitary) unrelated to thyroid hormone receptor cross-reactivity; thyroid storm does not occur on glucocorticoid withdrawal.
• Option E: Option E is incorrect -- while glucocorticoids do have weak mineralocorticoid activity, the primary risk on abrupt withdrawal is glucocorticoid deficiency, not hypokalemia from mineralocorticoid loss; hypokalemia is actually a side effect of exogenous glucocorticoids (due to mineralocorticoid activity), not their withdrawal.